Therefore, our probes could potentiallyserve as diagnostic tools with further endeavors, as PARK7 is a potentialbiomarker for various cancers and Parkinson’s diseases.44−47 In addition, we further developed a first-in-class selective PARK7degrader JYQ-194 that induced PARK7 degradation in differenttumor cell lines. This evidence concerns the gene PARK7 and cancer.